SUMMARY
This article will give an overview of the key studies in chronic lymphocytic leukaemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) that were presented at the 2022 annual meeting of the American Society of Hematology. In CLL, topics mainly focused on the combination of novel agents and there are new data from head-to-head comparison of different Bruton’s Tyrosine Kinase inhibitors (BTKi). In follicular lymphoma, bispecific T-cell engagers continue to make their introduction in the therapeutic landscape, whereas CAR-T cells are showing durable responses.
(BELG J HEMATOL 2023;14(1):16–8)
